1 domain / 2 areas / 2 specializations
NYU Center for Psychedelic Medicine
NYU Langone Health’s Center for Psychedelic Medicine (NYU CPM) conducts health-focused translational research, education, and training on the therapeutic use of psychedelic drugs across psychiatry, medicine, and preclinical science. It supports clinical trials and a research training program to develop investigators and clinicians in the field.
Academic Research
0 papersPublished Papers
0
Trial Involvement
0
Distinct Focus Topics
0
Latest Publication
Unknown
Government funding received
3 grantsNIDA — Psilocybin for opioid use disorder (landmark $15M trial)
2024–2029
PI: Michael Bogenschutz (Director, NYU Langone Center for Psychedelic Medicine). $3M/year for 5 years, contingent on progress in first 2. Phase 2 double-blind multi-site RCT evaluating psilocybin in patients with OUD who continue to use non-prescribed opioids despite methadone adherence. Collaboration with Carey Turnbull's non-profit B.More.
SourceNIAAA — Psilocybin for alcohol use disorder (Phase 2 fMRI mechanistic trial)
2024
PI: Michael Bogenschutz (NYU Langone). Double-blind, randomised, placebo-controlled Phase 2 trial of psilocybin (30 mg vs inactive placebo) in AUD patients using fMRI biomarkers. Conducted at NYU and Silver Hill Hospital.
SourceNCI R01CA268521 — Psilocybin for cancer-related psychiatric and existential distress
2022–2027
Two-site, double-blind, active-placebo RCT (n=200) of single 25 mg psilocybin vs 100 mg niacin in advanced-cancer patients with baseline psychiatric distress, evaluating effects on anxiety, depression, demoralisation, death anxiety, and quality of life. Multi-PI: Stacy M. Fischer (CU Anschutz, contact PI) and Stephen Ross (NYU Langone Center for Psychedelic Medicine). Funded by the NCI Division of Cancer Prevention. Amount shown is total awarded to date across FY2022-FY2025 per NIH RePORTER ($681K + $652K + $632K + $662K = $2.63M); project runs through June 2027 with two more fiscal years expected.
SourceQuick Facts
- Website
- Visit